Kornimate/medical-research-clean huggingface dataset:
nutritional intervention for biliary atresia

Conditions: Nutrition Disorder, Infant; Biliary Atresia

Summary: infants with biliary atresia (biliary atresia, ba) have an increased risk of malnutrition due to insufficient dietary intake to maintain normal growth, impaired intestinal absorption, increased metabolic rate, and damage to some liver macronutrient metabolic pathways. the medium-chain triglyceride formula (mct) in enteral nutrition has advantages: (1) it has a fast metabolism in the liver and possesses the advantage of being an innate energy source; (2) it can share metabolic pathways with some other fatty acids (dha, epa), and can promote the synthesis of phospholipids, etc. therefore, en containing the mct formula is regarded as an important approach to alleviate growth retardation in ba children and improve the nutritional status of patients. this study aims to observe the effect of intensified enteral feeding with a high mct formula during the perioperative period compared to traditional oral feeding on the prognosis of children with biliary atresia. the method adopted is a prospective, two-arm, open-label, multicenter, and interventional real-world study.


Eligibility criteria:
inclusion criteria: * 1. infants under 3 months old; 2. children clinically diagnosed with biliary atresia and in need of kasai surgery; 3. the patient themselves, legal representative or guardian have signed the informed consent form and are willing to actively cooperate with treatment and follow-up. exclusion criteria: * 1. low birth weight infants or very low birth weight infants; 2. complicated with life-threatening diseases of various organ systems; 3. complicated with other severe digestive tract malformations or other diseases that may interfere with the treatment of the patient or the patient's compliance; 4. patients who have participated in other clinical trials within the last month; 5. any other conditions that the researcher deems unsuitable for participation in this trial.
history of hepatitis c in volunteer blood donors

Conditions: Hepatitis C

Summary: hepatitis c is a disease of the liver caused by the hepatitis c virus (hcv). patients with hepatitis c may feel well and show no signs or symptoms of being ill. however, researchers would like to study the long-term effects of this disease. volunteer blood donors diagnosed with chronic hepatitis c viral (hcv) and various levels of liver enzyme activity will be offered a complete medical evaluation and liver biopsy. the tests will enable researchers to provide the patients with an idea of how severe their liver disease is. the virus and patient will be studied in order to understand why patients with hepatitis c develop different levels of liver damage.

a selected sample of volunteer blood donors with chronic hepatitis c viral (hcv) infection and various levels of serum aminotransferase activity will be offered a complete medical evaluation and liver biopsy to determine the severity of their liver disease. various virological and host factors will be studied in an attempt to determine why patients with hcv infection develop differing degrees of liver disease.

Eligibility criteria:
patients with chronic hepatitis c. age 18 to 70 years, male or female. hcv infection indicated by the presence of anti-hcv (by elisa and recombinant immunoblot assay \[riba\]). written informed consent. women must not be pregnant. patients must not have significant systemic illnesses other than liver disease, including congestive heart failure, renal failure, uncontrolled diabetes mellitus. patients must not have antiviral or immunosuppressive therapy within the last 6 months. patients must not have hiv infection. patients must not have contraindications to liver biopsy (mainly clotting abnormality (coumadin therapy, platelet count less than 50,000/cubic millimeter, prothrombin time more than 4 seconds beyond control)).

Keywords: aminotransferases anti-hcv blood donors hcv rna hepatitis c liver biopsy serum aminotransferases transfusion
electroencephalography activity in individuals with nonspecific chronic low back pain after cranial osteopathic manipulative treatment

Conditions: Low Back Pain

Summary: osteopathic medicine is based on a diagnostic and therapeutic system to treat tissue mobility/ motility dysfunctions in general, using different approaches (depending on the target tissue) known as osteopathic manipulative treatment. among all the available techniques those ones addressed to the cranial field are most questioned because of the lack of scientific evidence; but the compression of the 4th ventricle technique has been largely studied in clinical trials. studies have shown that the technique may affect both central and autonomous nervous system, modulating some reflexes (traube-hering baro signal), and modifying brain cortex electrical activity through central sensitization in subjects with chronic low back pain. thus, investigators hypothesize that the compression of the 4th ventricle may modulate peak alpha frequency (electroencephalographic assessment) and promote physical relaxation in subjects in vigil.

a randomized controlled crossover trial with blinded assessor was designed to test the hypothesis. a total of 81 participants will be assigned to three treatment conditions, with seven days of washout: compression of the 4th ventricle group; sham compression of the 4th ventricle group; control group (no intervention). all participants will be recruited at the outpatient rehabilitation service of the university hospital of brasília - university of brasília (brazil).

Eligibility criteria:
inclusion criteria: * participants over 18 years old with self-reported nonspecific chronic low back pain will be recruited exclusion criteria: * participants suffering from secondary chronic low back pain, * fever, chills, sweating, weight loss, asthenia, anorexia; * cardiovascular and respiratory symptoms such as chest pain, dyspnea and cough; * headache, dizziness, lightheadedness, fainting, tremors, dysarthria and aphasia; * participants who underwent surgery on the spine; * diagnosis of any neurological, cardiac, respiratory and rheumatic disease; * regular use of drugs with effects on the central nervous system.

Keywords: low back pain osteopathic manipulations electroencephalography
helicobacter pylori rescue treatment in patients allergic to penicillin

Conditions: Helicobacter Pylori Infection

Summary: the purpose of this study is to assess and compare the effectiveness of furazolidone-tetracycline-containing and metronidazole-tetracycline-containing quadruple regimens for the rescue treatment of helicobacter pylori infection inpatients allergic to penicillin.

helicobacter pylori(h.pylori), which infects about 50% of the global population,has been recognized as a main risk factor of multiple gastric pathologies,especially non-cardiac gastric cancer. strongly evidence supports that h.pylori eradication is an effective approach to reduce the incidence of those pathologies.however,helicobacter pylori eradication is a challenge in patients allergic to penicillin. therefore, the investigators aim to assess and compare the effectiveness of furazolidone-tetracycline-containing and metronidazole-tetracycline-containing quadruple regimens for the rescue treatment of helicobacter pylori infection in patients allergic to penicillin.

Eligibility criteria:
inclusion criteria: * patients aged 18-70 with h. pylori infection. * patients with previous helicobacter pylori eradication. * patients allergic to penicillin. exclusion criteria: * patients treated with h2-receptor antagonist, ppi, bismuth and antibiotics in the previous 4 weeks. * patients with gastrectomy, acute gi bleeding and advanced gastric cancer. * patients with known or suspected allergy to study medications. * currently pregnant or lactating. * inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.

Keywords: helicobacter pylori eradication allergic penicillin tetracycline
effectiveness of two exercise programs on the neck.

Conditions: Subjects With Deep Cervical Muscle Strength Deficit

Summary: the purpose of this study is to evaluate the clinical results in lower cervical range of motion, size deep muscles, endurance, craniovertebral angle and cervical propioception by a training protocol with the new device for cervical treatment (cdat) and the conventional training protocol (ct) versus a control group (c) in subjects with cervical deep muscle strength deficit.

neck pain is one of the major public health problems, which has a great impact on people's lives, with high prevalence and recurrence rate. cervical vertebral column is heavily dependent on the muscles for its physical support and activities. there are increasing evidences to support that cervical muscles may impair in patients with neck disorders. training protocols can help to improve pain, cervical function, posture and cross-sectional area. however, there are no training protocols in subjects with strength deficit of deep cervical muscles, including deep neck extensor and flexor muscles. the cervical device treatment (cdat) allows us to train the cervical flexor and extensor muscle in a simple and comfortable way.

Eligibility criteria:
inclusion criteria: * deep flexor strength deficit in craniocervical flexion test. * deep extensor strength deficit in neck extensor muscle endurance. * ≤ 14 score in neck disability index exclusion criteria: * have received cervical treatment during the last six month, presented any red flag, neurological or cognitive impairment (inability to understand the questionnaires or examination). * have received cervical manual therapy treatment during the last six month. * a history of cervical trauma or surgery during the last year. * chronic neck pain occurring during the last six months (intensity, visual analogue scale \>3/10, frequency \> 2 days/week, duration \>3 hours/day).

Keywords: neck muscles neck pain exercise therapy telerehabilitation muscle weakness
feasibility study of a nurse intervention to impact mucositis severity and prevent dehydration

Conditions: Lung Cancer; Mucositis Oral; Dehydration; Head and Neck Cancer

Summary: this is a descriptive mixed method pilot study to determine the feasibility of a tailored nurse-delivered telephone intervention designed to impact mucositis symptom severity and prevent dehydration in lung and head/neck cancer patients undergoing chemoradiation, therefore reducing overall symptom severity and improving quality of life. secondary purposes for this study are to investigate if the nursing intervention can decrease lung and head/neck cancer patients' unscheduled medical visits between chemoradiation treatments.


Eligibility criteria:
inclusion criteria: * non-small cell or limited stage small cell lung cancer or head \& neck cancer * over 18 years old * eligible for concurrent chemoradiation in the first line setting * eastern cooperative group 0-2 (able to complete activity of daily living (adls) independently or with assistive device only) * able to read \& write english or spanish exclusion criteria: * under 18 years old * underlying anxiety or depression (must pass screening tools) * medically diagnosed with a cognitive impairment * no prior chemotherapy or radiation treatment * no access to a telephone * blind or deaf or illiterate * requires assistance with self-care adls
ssnhl in head & neck cancer patients

Conditions: Hearing Loss

Summary: a sound dosimeter will be used to measure noise level to which a population of head and neck patients on the otolaryngology ward are exposed to. the device is the extech 407764 type ii sound level meter (iec 651 rs232). the device will be configured to osha and iso standards, and calibration confirmed in a sound booth with a sound level calibrator. the dosimeter captures a-weighted sound levels between 30 and 130 db. specifically, participants included in the study will be head and neck cancer patients on the otolaryngology floor at vg site. measurements will be taken three times a day at random intervals. each measurement will be taken in a similar manner. the dosimeter will be placed on the head side of the bed at the level of patient's ear one inch away from the ear and kept there for ten seconds to get a representative level. the overall measurements will be averaged (leq) for statistical analysis. investigators will randomly select 50% of the patients and give them protective ear plugs to be used while the participants are inpatients, and the other 50% will not provide them with ear plugs (like what is being done now). investigators will obtain a baseline hearing test prior to admission and 7 days after admission and then a repeat hearing test at 3 weeks after discharge. the goal is to establish if there is a temporary or a permanent threshold shift.


Eligibility criteria:
inclusion criteria: * clinical diagnoses of head and neck disease requiring surgery. * must be expected to be admitted to ent floor. * must be able to conduct a hearing test. exclusion criteria: * a diagnoses of snhl. * participants with low mental capacity.
oxalate excretion profile in patients with a heterozygous mutation of the agxt (alanine-glyoxylate aminotransferase) gene

Conditions: Hyperoxaluria (Disorder)

Summary: primary hyperoxaluria type i (ph1) is a rare genetic disorder responsible for severe lithiasis leading to progressive deterioration of renal function and end-stage renal failure. ph1 is linked to a deficiency in glyoxylate amino transferase (agxt), which leads to increased endogenous oxalate synthesis and hyperoxaluria. in the urine, urinary oxalate precipitates with calcium, forming insoluble crystals, leading to lithiasis and the development of nephrocalcinosis. non-genetic etiologies of oxalic nephropathy are well known, in particular enteric causes (malabsorptions, bypass, calcium deficiencies, etc.) and sometimes linked to increased oxalate intake in the form of nutritional or vitamin supplements, reinforcing the hypothesis of probably underestimated favouring factors of hyperoxaluria. until now, heterozygous patients with a mutation in the agxt gene were considered asymptomatic. however, there have been several cases of patients with heterozygous agxt mutations presenting with lithiasis. consequently, the characteristics of symptomatic and asymptomatic heterozygous patients will be studied in order to define the elements that would explain the expression of the disease (particularities of the agxt mutation, presence of another heterozygous mutation or favorable living conditions). the hypothesis is that there is an increase in hepatic oxalate production in heterozygous patients, which explains why they remain asymptomatic under usual conditions, but could favor stone formation under favorable conditions such as severe calcium deficiency or malabsorption.


Eligibility criteria:
inclusion criteria: * presenting an heterozygous mutation on agxt * presenting symptoms (presence or history of stones, nephrocalcinosis) or not exclusion criteria: * individuals unable to provide 24-hour urine samples. * individuals unable to free up a morning for day hospital appointments * individuals deprived of liberty by a judicial or administrative decision. * adults under a legal protection measure (guardianship, trusteeship). * individuals placed under judicial protection. * participants enrolled in another study with an ongoing exclusion period * pregnant women. * individuals not covered by social security

Keywords: agxt heterozygous mutation lithiasis nutrition nephropathy
study of bms-477118 as monotherapy with titration in subjects with type 2 diabetes who are not controlled with diet and exercise

Conditions: Diabetes

Summary: the purpose of this trial is to understand if saxagliptin is more effective than placebo as a treatment for type 2 diabetic subjects who are not controlled with diet and exercise

all subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. subjects who complete the short-term period will be eligible to enter the long term extension period. also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive metformin (rescue medication) added onto their blinded study medication

Eligibility criteria:
inclusion criteria: * type 2 diabetes * inadequate blood sugar control exclusion criteria: * previous treatment for diabetes * current treatment with other medications to lower blood sugar * major heart, liver or kidney problems * women who are pregnant or breastfeeding
study to investigate the mass balance, metabolism, and excretion of [14c]-pf-07304814 in healthy participants

Conditions: Healthy

Summary: this open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of pf 07304814 administered at a dose of 500 mg \[14c\] pf-07304814 containing approximately 420 nci \[14c\] pf-07304814 as a constant-rate, continuous iv infusion over 24 hours


Eligibility criteria:
inclusion criteria: 1. male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the icd. 2. participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ecgs. 3. participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 4. bmi of 18 to 32 kg/m2; and a total body weight \>50 kg (110 lb). exclusion criteria: 1. evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). 2. positive test result for sars-cov-2 infection at the time of screening or day -1. 3. use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention. 4. previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). 5. participants who have received a covid-19 vaccine within the past 2 weeks; and/or participants who are scheduled to receive a second covid-19 vaccination dose during the in-clinical period of this study. 6. a positive urine drug test. 7. total 14c radioactivity measured in plasma exceeding 11 mbq/ml at "screening" . 8. females who are breastfeeding. 9. history of tobacco or nicotine use within 3 months prior to dosing, or a positive cotinine at screening or day -1. 10. participants enrolled in a previous radionucleotide study or who have received radiotherapy within 12 months prior to screening or such that total radioactivity would exceed acceptable dosimetry (ie, occupational exposure of 5 rem per year). 13. participants whose occupation requires exposure to radiation or monitoring of radiation exposure. 14. investigator site staff or pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Keywords: covid-19 sars-cov-2 viral disease
keravive by hydrafacial for scalp health and enhanced hair quality

Conditions: Androgenic Alopecia

Summary: the study aims to assess the efficacy and safety of keravive by hydrafacial treatments and keravive peptide spray for scalp health and enhancing hair quality in patients with androgenic alopecia. this study is intended to be a single arm study. suitable subjects who meet all inclusion criteria and consented will undergo 3 in-office keravive by hydrafacial treatments at day 0 and weeks 4 and 8 in combination with daily application on keravive peptide spray at home. subjects will be assessed at day 0, and weeks 4, 8, and 20 by investigators using the norwood scale (males), ludwig classification (females), and a series of likert scales for ranking improvement in scalp health and hair quality.

this study is intended to be a single arm study. suitable subjects who meet all inclusion criteria and consented will undergo 3 in-office keravive by hydrafacial treatments at baseline and weeks 4 and 8 in combination with daily application on keravive peptide spray at home. subjects will be assessed at baseline, and weeks 4, 8, and 20 by investigators using the norwood scale (males), ludwig classification (females), and a series of likert scales for ranking improvement in scalp health and hair quality. efficacy will be assessed through a series of dynamic and static questionnaires. investigators will complete static questionnaires at day 0 and weeks 4, 8 and 20 rating the subjects' hair appearance, thinning, and temporal line recession using likert scales. subjects will complete dynamic questionnaires at weeks 4, 8 and 20 to compare their current state to their baseline condition for scalp symptoms (itchiness, dryness, and flakiness) and hair quality (overall health, fullness, evenness, pigment, hair growth, and hair loss) using likert scales. subjects will also rank their hair appearance at day 0, week 4, 8, and 20. photography will be performed at each study visit. safety assessments will include investigator- and subject-reported adverse events (aes) during the study.

Eligibility criteria:
inclusion criteria: * norwood scale score of 2, 3 or 3 vertex (males) and ludwig classification of type i-1, i-2 or i-3 (females). exclusion criteria: * non-study hair loss treatments (e.g., dutasteride, finasteride, minoxidil, nutraceuticals, prp therapy, laser or led scalp treatments, etc.) * salon treatments such as straightening, perms or coloring.